EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The analysis of clinical efficacy and safety of graft-versus-host disease prophylaxis based on janus kinase inhibitors versus calcineurin inhibitors in children following allogeneic hematopoietic stem cell transplantation

Elena B. Machneva, E. V. Skorobogatova

Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 68-82

DOI: 10.24287/j.1117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Elena B. Machneva und 1 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Graft-versus-host disease (GVHD) remains one of the key factors limiting the success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in pediatric patients. Conventional calcineurin inhibitor (CNI)-based GVHD prophylaxis is associated with considerable organ toxicity and the risk of endothelial complications, and often fails to demonstrate sufficient efficacy. Aim: to analyze the efficacy and safety of janus kinase inhibitors (JAKi) in comparison with CNIs for GVHD prevention in children after allo-HSCT. Materials and methods. We retrospectively analyzed outcomes of allo-HSCT performed in 316 pediatric patients between 2019 and 2025. The patients were stratified into 2 subgroups: the group of interest and the control group. Patients in the group of interest (n = 158) received JAKi-based GVHD prophylaxis with ruxolitinib or tofacitinib while the control group (n = 158) underwent standard CNI-based therapy. The groups were comparable with respect to the major baseline characteristics that could influence allo-HSCT outcomes and the risk of GVHD, such as diagnosis, age and gender, and donor type. The only differences were follow-up duration (longer in the control group), the source of hematopoietic stem cells (peripheral blood stem cells were more frequently used in the group of interest) and the frequency of post-transplant cyclophosphamide (PTCy) use.

Results

JAKi-based regimens were found to have a statistically significant advantage over standard prophylaxis with CNIs in terms of reducing the incidence of acute GVHD (52.5% vs. 65.2%; p = 0.02), febrile neutropenia (44.3% vs. 70.9%; p = 0.00), endothelial complications (10.8% vs. 19.0%; p = 0.04), severe infections (20.9% vs. 34.0%; p = 0.01), and visceral toxicity (18.6% vs. 33.5%; p = 0.00). Furthermore, the use of JAKi resulted in faster leukopoiesis recovery compared to CNIs (a median of 17 vs. 20 days; p = 0.01), despite the more extensive use of PTCy. Particular emphasis was placed on the possibility of complete elimination of CNIs from prophylaxis regimens as well as the minimization of glucocorticoid use.

Conclusion

JAKi, in combination with adaptive PTCy regimens and targeted agents, form a new advanced strategy for GVHD prophylaxis in children. This approach reduces the incidence of endothelial complications and visceral toxicity, accelerates hematopoietic recovery, and minimizes steroid exposure and infectious complications after allo-HSCT, while ensuring the efficacy of prophylaxis even in patients at high risk of developing GVHD.

Zitieren

APA

Machneva, E. B., & Skorobogatova, E. V. (2026). The analysis of clinical efficacy and safety of graft-versus-host disease prophylaxis based on janus kinase inhibitors versus calcineurin inhibitors in children following allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology, 25(2), 68-82. https://doi.org/10.24287/j.1117

Vancouver

Machneva EB, Skorobogatova EV. The analysis of clinical efficacy and safety of graft-versus-host disease prophylaxis based on janus kinase inhibitors versus calcineurin inhibitors in children following allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):68-82. doi:10.24287/j.1117

BibTeX
@article{Machneva2026,
  author = {Machneva, Elena B. and Skorobogatova, E. V.},
  title = {The analysis of clinical efficacy and safety of graft-versus-host disease prophylaxis based on janus kinase inhibitors versus calcineurin inhibitors in children following allogeneic hematopoietic stem cell transplantation},
  journal = {Pediatric Hematology/Oncology and Immunopathology},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {68--82},
  doi = {10.24287/j.1117}
}
Kostenlos starten →